Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 49: 1957-1958, 2003; 10.1373/clinchem.2003.025452
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mead, G. P.
Right arrow Articles by Bradwell, A. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mead, G. P.
Right arrow Articles by Bradwell, A. R.
Related Collections
Right arrow Clinical Immunology
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2003;49:1957-1958.)
© 2003 American Association for Clinical Chemistry, Inc.

Letters

Measurement of Immunoglobulin Free Light Chains in Serum

Graham P. Mead1,a, Mark T. Drayson2, Hugh D. Carr-Smith1 and Arthur R. Bradwell2

1 The Binding Site Ltd., PO Box 4073, Birmingham B29 6AT, UK

2 Department of Immunology, University of Birmingham, Birmingham B15 2TT, UK

aAuthor for correspondence.

The first 20% of the full text of this article appears below.


To the Editor:

In a recent issue of this journal, Tate et al. (1) reported studies using assays for free immunoglobulin light chains (FLCs) that we have been instrumental in developing (2). Although in general agreement with their findings, we would like to highlight some additional data that are pertinent to several of their comments.

Tate et al. (1) concluded that more clinical data were required before the assays are adopted for routine clinical use. Since the acceptance of their report, however, several relevant studies have been published. Bradwell et al. (3) presented data showing that 224 of 224 patients with Bence Jones myeloma could be identified based on abnormal serum concentrations of FLCs . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
E. S.K. Ma and E. T.K. Lee
A Case of IgM Paraproteinemia in Which Serum Free Light Chain Values Were Within Reference Intervals
Clin. Chem., February 1, 2007; 53(2): 362 - 363.
[Full Text] [PDF]

Home page
 Arch DermatolHome page
M. Q. Lacy, W. J. Hogan, M. A. Gertz, A. Dispenzieri, S. V. Rajkumar, S. Hayman, S. Kumar, M. R. Litzow, and A. L. Schroeter
Successful Treatment of Scleromyxedema With Autologous Peripheral Blood Stem Cell Transplantation
Arch Dermatol, October 1, 2005; 141(10): 1277 - 1282.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Association for Clinical Chemistry.